93 related articles for article (PubMed ID: 10767361)
1. A multivariate analysis for predicting cisplatin-induced delayed emesis.
Pivot X; Marghali N; Etienne MC; Bensadoun RJ; Thyss A; Otto J; François E; Renée N; Lagrange JL; Schneider M; Milano G
Oncol Rep; 2000; 7(3):515-9. PubMed ID: 10767361
[TBL] [Abstract][Full Text] [Related]
2. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
[TBL] [Abstract][Full Text] [Related]
3. Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis.
Bhatia A; Tripathi KD; Sharma M
Indian J Med Res; 2004 Sep; 120(3):183-93. PubMed ID: 15489556
[TBL] [Abstract][Full Text] [Related]
4. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin and emesis: aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin.
Gralla RJ; Rittenberg C; Peralta M; Lettow L; Cronin M
Oncology; 1996 Jun; 53 Suppl 1():86-91. PubMed ID: 8692558
[TBL] [Abstract][Full Text] [Related]
6. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
Bhatia A; Tripathi KD; Sharma M
Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464
[TBL] [Abstract][Full Text] [Related]
7. Drug treatment of chemotherapy-induced delayed emesis.
Tavorath R; Hesketh PJ
Drugs; 1996 Nov; 52(5):639-48. PubMed ID: 9118814
[TBL] [Abstract][Full Text] [Related]
8. Anthropometric and pharmacotherapeutic variables on acute emesis induced by cisplatin-containing chemotherapy.
Catalán Arlandis JL; Jiménez Torres NV
Ann Pharmacother; 2000 May; 34(5):573-9. PubMed ID: 10852082
[TBL] [Abstract][Full Text] [Related]
9. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research.
Support Care Cancer; 2000 May; 8(3):229-32. PubMed ID: 10789965
[TBL] [Abstract][Full Text] [Related]
10. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
[TBL] [Abstract][Full Text] [Related]
11. [Clinical studies of oral antiemetic drugs on delayed emesis induced by cancer chemotherapy].
Sawaguchi K; Yabushita H; Tsukada H; Yamada H; Noguchi M; Nakanishi M
Gan To Kagaku Ryoho; 1999 Jan; 26(1):117-23. PubMed ID: 9987507
[TBL] [Abstract][Full Text] [Related]
12. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
[TBL] [Abstract][Full Text] [Related]
13. The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret.
Rudd JA; Jordan CC; Naylor RJ
Br J Pharmacol; 1996 Nov; 119(5):931-6. PubMed ID: 8922742
[TBL] [Abstract][Full Text] [Related]
14. Prevention of nausea and vomiting (N&V) in cancer patients receiving high-dose cisplatin. Assessment of the potential antiemetic activity of transdermal fentanyl (TTS-F) compared to standard antiemetic treatment in acute and delayed N&V: first clinical report.
Mantovani G; Curreli L; Macciò A; Massa E; Massa D; Mulas C; Succu G; Contu P
Anticancer Res; 1999; 19(4C):3495-502. PubMed ID: 10629642
[TBL] [Abstract][Full Text] [Related]
15. Management of cisplatin-induced delayed emesis.
Hesketh P
Oncology; 1996 Jun; 53 Suppl 1():73-7. PubMed ID: 8692555
[TBL] [Abstract][Full Text] [Related]
16. 5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis.
Ossi M; Anderson E; Freeman A
Oncology; 1996 Jun; 53 Suppl 1():78-85. PubMed ID: 8692556
[TBL] [Abstract][Full Text] [Related]
17. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
Kris MG; Tyson LB; Clark RA; Gralla RJ
Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282
[TBL] [Abstract][Full Text] [Related]
18. Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. The Italian Group for Antiemetic Research.
J Clin Oncol; 1993 Dec; 11(12):2396-404. PubMed ID: 8246029
[TBL] [Abstract][Full Text] [Related]
19. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.
Kris MG; Gralla RJ; Clark RA; Tyson LB; O'Connell JP; Wertheim MS; Kelsen DP
J Clin Oncol; 1985 Oct; 3(10):1379-84. PubMed ID: 4045527
[TBL] [Abstract][Full Text] [Related]
20. Double-blind, multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cisplatin in adult patients with cancer.
Passalacqua R; Cocconi G; Caminiti C; Silingardi V; Bella MA; Bichisao E; Michiara M; Malavasi V; Donati D; Di Costanzo F; Rocca A; Di Sarra S; Scaglione F; Fraschini F
J Clin Oncol; 1997 Jun; 15(6):2467-73. PubMed ID: 9196163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
